WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...
Patients with relapsed/refractory CLL who received zanubrutinib achieved significantly superior PFS compared with ibrutinib. The prescribing information for Brukinsa ® (zanubrutinib) has been updated ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the ...
Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial Across the 42 analysis units and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results